Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of “Reduce” from Brokerages

Simulations Plus, Inc. (NASDAQ:SLP) has earned an average recommendation of “Reduce” from the eight analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $17.25.

A number of research analysts have recently weighed in on the stock. William Blair cut shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Craig Hallum cut Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings raised Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter Woltosz sold 4,177 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total value of $77,023.88. Following the transaction, the director directly owned 3,202,131 shares of the company’s stock, valued at $59,047,295.64. This trade represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.10% of the company’s stock.

Institutional Trading of Simulations Plus

Several large investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in Simulations Plus during the 2nd quarter worth $25,000. Quarry LP bought a new position in Simulations Plus during the third quarter worth $28,000. GAMMA Investing LLC boosted its holdings in shares of Simulations Plus by 26.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after buying an additional 585 shares during the period. PNC Financial Services Group Inc. boosted its stake in Simulations Plus by 59.3% in the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock valued at $53,000 after acquiring an additional 1,669 shares during the period. Finally, Fifth Third Bancorp acquired a new position in Simulations Plus during the 1st quarter valued at approximately $54,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Shares of SLP opened at $18.43 on Monday. The firm has a market capitalization of $372.84 million, a P/E ratio of 46.07 and a beta of 1.33. The firm’s 50-day moving average is $18.33 and its two-hundred day moving average is $15.63. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $21.01.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The firm had revenue of $21.89 million during the quarter, compared to analysts’ expectations of $20.90 million.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.